Poolbeg Pharma Plc CEO Jeremy Skillington says the company has received full regulatory approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza.
Speaking to Proactive, Skillington said the regulatory green light is a major milestone for the clinical stage infectious disease pharmaceutical company.
“When Poolbeg IPO’d roughly this time last year we did state that we planned to be in the clinic with POLB 001 by the summer of 2022 so we’re hitting our milestones which is terrific,” Skillington said.
“Obviously investors like to see this as it builds confidence.”
